Upadacitinib for Blepharitis

Recruiting in Palo Alto (17 mi)

Overseen byWalter Liszewski

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: Northwestern University

No Placebo Group

Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?

This study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing.

Eligibility Criteria

This trial is for individuals with persistent eyelid dermatitis, which hasn't improved after using topical treatments and undergoing patch testing. Specific eligibility details are not provided.

Inclusion Criteria

Willing and able participants that comply with study activities

I have tried at least one prescription cream for my eyelid dermatitis without success.

I am between 18 and 70 years old and have had eyelid dermatitis for at least two months.

See 2 more

Exclusion Criteria

Self-reported history of allergic response to upadacitinib

I am not pregnant, nursing, or planning to become pregnant during the study.

I am using topical medications for eyelid dermatitis and started within the last week.

See 6 more

Treatment Details

Interventions

Upadacitinib (Janus Kinase Inhibitor)

Trial OverviewThe study is evaluating the effectiveness of a medication called Upadacitinib at a dose of 15 MG in treating refractory eyelid dermatitis.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Upadacitinib TreatmentExperimental Treatment1 Intervention

Participants on upadacitinib 15mg daily

Upadacitinib is already approved in European Union, United States, Canada for the following indications:

🇪🇺 Approved in European Union as Rinvoq for: